Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine | Zendy

Lewis McCurdy | Zendy; Brenda Larkin | Zendy; Jennifer E. Martin | Zendy; Barney S. Graham | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine

Author(s) -

Lewis McCurdy,

Brenda Larkin,

Jennifer E. Martin,

Barney S. Graham

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/421266

Subject(s) - smallpox , smallpox vaccine , vaccinia , medicine , vaccination , virology , immunity , variola virus , modified vaccinia ankara , immunology , immune system , biology , biochemistry , gene , recombinant dna

Despite the declaration of smallpox eradication in 1980, the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained. Although the currently available vaccine was used for the most successful medical intervention ever accomplished, it also is associated with side effects that are difficult to accept in a vaccine for a disease that has not been present for >25 years. Herein, we review alternative approaches to maintaining immunity to smallpox through vaccination with attenuated poxviruses, and we suggest modified vaccinia Ankara (MVA) as a leading candidate for an alternative smallpox vaccine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research